AstraZeneca and Daiichi Sankyo’s TROP2-directed antibody-drug conjugate failed a key survival endpoint in a late-phase breast ...

The former head of vaccine R&D at GSK has pulled together $100 million for a London-based biotech working on respiratory ...

Another biotech startup revealed plans Friday evening for an initial public offering, making it the sixth startup to list new ...

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every ...

Despite largely exiting oncology, Sanofi continues to reap the benefit of its multiple myeloma treatment Sarclisa. The FDA on ...

The US Court of Appeals for the Fifth Circuit is reviving PhRMA's legal attack on Medicare drug price negotiations. On Friday ...

This week, a letter surfaced in which Eli Lilly asked for a patient to release medical information so it could contact her ...

The US' Health Resources and Services Administration threatened Johnson & Johnson with fines for unilaterally reshaping the ...

Yuhan and Johnson & Johnson Innovative Medicine (JJIM), formerly known as Janssen, ended a research project after securing ...

After a second review, the FDA approved Zevra Therapeutics’ treatment for Niemann-Pick disease type C, a progressive rare ...

An early-stage biotech investor called YK Bioventures plans to raise $100 million, according to an SEC filing on Wednesday.

Novo Nordisk's $1 billion bet last year on a small Canadian biotech could expand the Danish drug giant's arsenal of obesity medicines, but it will first have to address safety concerns. On Friday, Nov ...